Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages.

Li G, Zhai Y, Wang Z, Wang Z, Huang R, Jiang H, Li R, Feng Y, Chang Y, Jiang T, Zhang W.

Cancer Med. 2019 Dec 18. doi: 10.1002/cam4.2754. [Epub ahead of print]

2.

Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.

Gao WZ, Guo LM, Xu TQ, Yin YH, Jia F.

J Transl Med. 2018 Dec 20;16(1):368. doi: 10.1186/s12967-018-1744-8.

3.

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.

Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, Karikari IO, Grossi PM, Thomas S, Friedman AH, Adamson C.

J Neurosurg. 2016 Apr;124(4):998-1007. doi: 10.3171/2015.4.JNS142200. Epub 2015 Oct 9.

PMID:
26452121
4.

Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.

Shwetha SD, Shastry AH, Arivazhagan A, Santosh V.

Pathol Res Pract. 2016 Jan;212(1):17-23. doi: 10.1016/j.prp.2015.11.002. Epub 2015 Nov 14.

PMID:
26616112
5.

Potential clinical role of telomere length in human glioblastoma.

La Torre D, Aguennouz M, Conti A, Giusa M, Raffa G, Abbritti RV, Germano' A, Angileri FF.

Transl Med UniSa. 2011 Oct 17;1:243-70. Print 2011 Sep.

6.

Variegated Colors of Pediatric Glioblastoma Multiforme: What to Expect?

Immanuel V, Kingsley PA, Negi P, Isaacs R, Grewal SS.

Rare Tumors. 2017 Aug 29;9(2):6552. doi: 10.4081/rt.2017.6552. eCollection 2017 Jul 3.

7.

Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.

Liu B, Liu J, Liao Y, Jin C, Zhang Z, Zhao J, Liu K, Huang H, Cao H, Cheng Q.

Med Sci Monit. 2019 May 16;25:3624-3635. doi: 10.12659/MSM.916648.

8.

An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.

Sintupisut N, Liu PL, Yeang CH.

Nucleic Acids Res. 2013 Oct;41(19):8803-21. doi: 10.1093/nar/gkt656. Epub 2013 Jul 31.

9.

Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.

Lukács G, Tóth Z, Sipos D, Csima M, Hadjiev J, Bajzik G, Cselik Z, Semjén D, Repa I, Kovács Á.

Ideggyogy Sz. 2018 Mar 30;71(3-04):95-103. doi: 10.18071/isz.71.0095.

PMID:
29889468
10.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
11.

A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.

Chai R, Zhang K, Wang K, Li G, Huang R, Zhao Z, Liu Y, Chen J.

J Cancer Res Clin Oncol. 2018 Mar;144(3):439-447. doi: 10.1007/s00432-017-2572-6. Epub 2018 Jan 3.

PMID:
29299749
12.

Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.

Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.

Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7.

PMID:
25723791
13.

The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.

Burri SH, Gondi V, Brown PD, Mehta MP.

Am J Clin Oncol. 2018 Feb;41(2):191-196. doi: 10.1097/COC.0000000000000395. Review.

15.

Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: An analysis of the National Cancer Data Base.

Amsbaugh MJ, Yusuf MB, Gaskins J, Burton EC, Woo SY.

Cancer. 2017 Sep 1;123(17):3277-3284. doi: 10.1002/cncr.30730. Epub 2017 Apr 27.

16.

A 63 signature genes prediction system is effective for glioblastoma prognosis.

Zhang Y, Xu J, Zhu X.

Int J Mol Med. 2018 Apr;41(4):2070-2078. doi: 10.3892/ijmm.2018.3422. Epub 2018 Jan 25.

17.

Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance.

Kostopoulou ON, Mohammad AA, Bartek J Jr, Winter J, Jung M, Stragliotto G, Söderberg-Nauclér C, Landázuri N.

Int J Cancer. 2018 Mar 15;142(6):1266-1276. doi: 10.1002/ijc.31132. Epub 2017 Nov 7.

19.

Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.

Ciammella P, Galeandro M, D'Abbiero N, Podgornii A, Pisanello A, Botti A, Cagni E, Iori M, Iotti C.

Clin Neurol Neurosurg. 2013 Sep;115(9):1609-14. doi: 10.1016/j.clineuro.2013.02.001. Epub 2013 Feb 26.

PMID:
23453151
20.

Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.

Kim JH, Choi SH, Ryoo I, Yun TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH.

PLoS One. 2014 Nov 24;9(11):e113587. doi: 10.1371/journal.pone.0113587. eCollection 2014.

Supplemental Content

Support Center